Clinical Trial Update: Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer [Phase 1]

View source ↗

Summary

A Phase 1 trial of Biomea Fusion's covalent menin inhibitor BMF-219 in KRAS-driven non-small cell lung cancer, pancreatic cancer, and colorectal cancer has been…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer
• Pancreatic Cancer

Drugs mentioned

• BMF-219 (covalent menin inhibitor)

Snippet

Sponsor: Biomea Fusion Inc. | Conditions: Non Small Cell Lung Cancer, Pancreatic Cancer | Phase 1 | Status: TERMINATED